- Main
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
- Author(s): Ng, Dianna L
- Goldgof, Gregory M
- Shy, Brian R
- Levine, Andrew G
- Balcerek, Joanna
- Bapat, Sagar P
- Prostko, John
- Rodgers, Mary
- Coller, Kelly
- Pearce, Sandra
- Franz, Sergej
- Du, Li
- Stone, Mars
- Pillai, Satish K
- Sotomayor-Gonzalez, Alicia
- Servellita, Venice
- Martin, Claudia Sanchez San
- Granados, Andrea
- Glasner, Dustin R
- Han, Lucy M
- Truong, Kent
- Akagi, Naomi
- Nguyen, David N
- Neumann, Neil M
- Qazi, Daniel
- Hsu, Elaine
- Gu, Wei
- Santos, Yale A
- Custer, Brian
- Green, Valerie
- Williamson, Phillip
- Hills, Nancy K
- Lu, Chuanyi M
- Whitman, Jeffrey D
- Stramer, Susan L
- Wang, Candace
- Reyes, Kevin
- Hakim, Jill MC
- Sujishi, Kirk
- Alazzeh, Fariba
- Pham, Lori
- Thornborrow, Edward
- Oon, Ching-Ying
- Miller, Steve
- Kurtz, Theodore
- Simmons, Graham
- Hackett, John
- Busch, Michael P
- Chiu, Charles Y
- et al.
Published Web Location
https://doi.org/10.1038/s41467-020-18468-8Abstract
Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.